Exhibit 10.24

 
AMENDMENT No. 1 TO RESEARCH
AGREEMENT
 
This Amendment No. 1 to Research Agreement ("Amendment") is made and entered into as of November 2, 2012 by and between Actinium Pharmaceuticals, Inc., ("Sponsor") and The University of Texas M.D. Anderson Cancer Center ("Institution"), a member institution of the University of Texas System ("System").
 
RECITALS
 
A.  
Sponsor and Institution entered into a Sponsored Research Agreement on August 6, 2012 (the "Agreement").
 
B.  
Sponsor and Institution wish to amend the terms of the Agreement as set forth below.
 
NOW, THEREFORE, it is hereby agreed as follows:
 
1.  
Amended Exhibit C - part 1 as enclosed replaces the same Exhibit C - part 1 from the Clinical Trial Agreement between The University of Texas M.D. Anderson Cancer Center and Actinium Pharmaceuticals, Inc. dated August 6, 2012.
 
2.  
Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as provided therein.
 
IN WITNESS WHEREOF, Sponsor and Institution have entered into this Amendment effective as of the date first set forth above.
 
ACTINIUM PHARMACEUTICALS, INC.   THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER  
           
By:  
/s/ Dragan Cicic
  
By: 
/s/ Renee Gonzales
  
 
Dragan Cicic, MD
    
Renee Gonzales
  
 
Title: COO/CMO 
    
Title: Assistant Director, Sponsored Programs
  
           
Date: November 2, 2012      Date: November 28, 2012     
 
 
Read and Understood
  
       
 
By:
/s/ Farhad Ravandi-Kashani  
   
Farhad Ravandi-Kashani,M.D.
  
   
Title: Principal Investigator
  
     
 
Date: November 26, 2012   
  
             
[Notary Seal]
 
1
 
 
 
2